Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
The role of histone deacetylase inhibitors in metastatic breast cancer / B. Zucchetti, A.K. Shimada, A. Katz, G. Curigliano. - In: THE BREAST. - ISSN 0960-9776. - 43(2019 Feb), pp. 130-134.
Titolo: | The role of histone deacetylase inhibitors in metastatic breast cancer |
Autori: | |
Parole Chiave: | Breast cancer; Epigenetic; Histone acetylation; Surgery |
Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica |
Data di pubblicazione: | feb-2019 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.breast.2018.12.001 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
HDAC Curigliano.pdf | Publisher's version/PDF | Administrator Richiedi una copia |